Haleon (NYSE:HLN) Stock Rating Raised to Hold at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank upgraded Haleon from “sell” to “hold,” while analyst opinion remains mixed. MarketBeat reports a “Moderate Buy” consensus rating and a $4.90 average target price.
• Haleon shares opened at $8.55, near their one-year low of $8.38 and below their 50-day and 200-day moving averages of $9.56 and $9.78, respectively.
• Institutional investors increased their positions in Haleon during the third quarter, although hedge funds and other institutions collectively own only 6.67% of the stock.

Haleon (NYSE:HLN - Get Free Report) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating in a report issued on Friday, MarketBeat Ratings reports.

HLN has been the topic of a number of other research reports. Zacks Research lowered Haleon from a "hold" rating to a "strong sell" rating in a research report on Thursday, October 22nd. Morgan Stanley restated an "overweight" rating on shares of Haleon in a research report on Thursday, August 6th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Haleon in a research note on Wednesday, September 23rd. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Haleon in a report on Tuesday, August 11th. Finally, Berenberg Bank reissued a "buy" rating on shares of Haleon in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $4.90.

Haleon Stock Performance

Shares of HLN stock opened at $8.55 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The firm has a market cap of $37.68 billion, a P/E ratio of 21.94, a P/E/G ratio of 2.26 and a beta of 0.14. The firm's 50 day moving average price is $9.56 and its 200-day moving average price is $9.78. Haleon has a one year low of $8.38 and a one year high of $11.28.

Institutional Investors Weigh In On Haleon

Several large investors have recently added to or reduced their stakes in HLN. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Haleon by 4.9% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company's stock worth $42,409,000 after purchasing an additional 219,567 shares in the last quarter. Profund Advisors LLC raised its stake in Haleon by 12.1% in the third quarter. Profund Advisors LLC now owns 55,100 shares of the company's stock valued at $496,000 after buying an additional 5,929 shares in the last quarter. Vise Technologies Inc. lifted its holdings in Haleon by 48.0% during the 3rd quarter. Vise Technologies Inc. now owns 79,286 shares of the company's stock worth $714,000 after buying an additional 25,697 shares during the last quarter. Founders Financial Securities LLC lifted its holdings in Haleon by 2.3% during the 3rd quarter. Founders Financial Securities LLC now owns 281,649 shares of the company's stock worth $2,535,000 after buying an additional 6,205 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its position in shares of Haleon by 22.0% during the 3rd quarter. D.A. Davidson & CO. now owns 18,462 shares of the company's stock worth $166,000 after acquiring an additional 3,330 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

About Haleon

Haleon plc NYSE: HLN is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company's products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.